The tyrosine kinase inhibitor of CSF-1R, PLX3397, reportedly improves the efficacy of immunotherapy by decreasing immunosuppressive TAMs in tumor tissues (Mok et al., 2014). This evidence concerns the gene CSF1R and neoplasm.